Trinity Biotech rises after saying it will focus on CGM technology

Trinity Biotech

13/03/2025 13:25

** Ireland-based commercial stage biotechnology company Trinity Biotech's TRIB.O shares rise 8.7% to $0.73 premarket

** Co says it will strengthen focus on its Continuous Glucose Monitoring (CGM) technology

** Says that the successful execution of its comprehensive transformation plan is expected to drive near-term profitability improvements

** Co also appoints Barclays as its exclusive financial advisor to support strategic realignment

** Up to Wednesday's close, stock had fallen 22.7% so far this year

 (Reporting by Anushka Chourasia)

 ((Anushka.Chourasia@thomsonreuters.com;))